Pfizer's $1.2 billion licensing deal with Biohaven for rights to oral migraine drug rimegepant is approaching a payoff after the European Commission approved the drug.
There's only one vaccine candidate for tick-borne infection Lyme disease in clinical development – Valneva and Pfizer's VLA15 – and it has just moved another step closer to being available.
Pfizer's Australian unit has tabled an offer to buy ResApp Health and its smartphone apps for the management and diagnosis of respiratory diseases in a deal that values the digital health c
The UK is poised to become the first country in the world to launch a new payment model for antibiotics that could reverse decades of decline in the category.
Last year, NICE said that Merck KGaA/Pfizer's Bavencio was too expensive for routine in NHS use as a first-line maintenance treatment for bladder cancer, even though the drug is the only ca
It is too early to consider widespread use of a second COVID-19 vaccine booster dose, according to the European Centre for Disease Prevention and Control (ECDC) and EMA's COVID-19 task forc